Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
|Articles|July 23, 2019
Cytena Establishes Subsidiary in Taiwan
Author(s)BioPharm International Editors
Cytena Bioprocess Solutions, a new Cytena subsidiary in Taiwan, will provide bioprocess solutions for pharmaceutical companies and research institutes.
Advertisement
Cytena, based in Freiburg, Germany, announced in a July 23, 2019 press release that it is establishing its subsidiary, Cytena Bioprocess Solutions, in Taiwan.
The subsidiary will provide bioprocess solutions for pharmaceutical companies and research institutes based on an innovative microbioreactor called C.Bird. The company says that the microbioreactor is the first to combine early-stage cell culture screening, monitoring, and optimization. The device enables customers to save several weeks of cell line development by selecting the right clones or cell cultures very early in the process.
"With the new R&D focused company, we want to further strengthen our global market position and open up new application areas and target markets,” said Jonas Schoendube, CEO of Cytena in Germany, in a press statement. “Our team in Taipei will enable us to be even closer to our Asian partners and use local R&D and production resources."
"It is fantastic to be working with Cytena to bring to market a new leading-edge technology for cell line development,” said Charles Tsai, CEO of Cytena Bioprocess Solutions, in a press statement. “By establishing a site in Asia, Cytena will build new connections and enable fast delivery of our products to our global customers."
Source:
Advertisement
Related to this article
Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
CordenPharma is expanding its Caponago, Italy site with a €80 million multi-year investment and new aseptic fill-finish lines, aiming to reach 500 million sterile injectable units of annual capacity to meet rising demand across peptide, biologic, LNP, and oligonucleotide-based drug products.
Solstice Oncology launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody licensed from Harbour BioMed, into neoadjuvant Phase 2 testing for microsatellite-stable colon cancer.
Encoded Therapeutics closed a $275 million Series F financing to fund pivotal and expansion studies of ETX101, an AAV9-mediated gene regulation therapy for SCN1A-positive Dravet syndrome, alongside commercial-scale buildout of the company's in-house GMP manufacturing.
Advertisement
Advertisement